The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1421
July 22, 2013
View Complete Issue         Table of Contents 2019 
Crofelemer (Fulyzaq) for Antiretroviral-Induced Diarrhea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Crofelemer (Fulyzaq) for Antiretroviral-Induced Diarrhea
July 22, 2013 (Issue: 1421)
The FDA has approved crofelemer (kroe fel’ e mer; Fulyzaq – Salix), a chloride channel inhibitor derived from the red sap of the South American plant Croton lechleri, for symptomatic relief of noninfectious diarrhea in patients with HIV...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Crofelemer (Fulyzaq) for Antiretroviral-Induced Diarrhea
Article code: 1421c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.